MAS1 and cancer: In a clinical trial performed by Petty WJ et al., Ang-(1-7) administration led to a decrease of plasma placental growth factor level in cancer patient with clinical benefit52, suggesting that the Ang-(1-7)/Mas pathway is a promising therapeutic target of ARDS.